Myonexus Therapeutics Announces Accelerated Acquisition by Sarepta Therapeutics Following Positive Preliminary Data from LGMD2E Program
Source: www.businesswire.com
Sarepta Therapeutics has exercised its option to acquire Myonexus Therapeutics for $165 million. Myonexus Therapeutics is a clinical-stage gene therapy company developing first-ever corrective gene therapies for Limb-girdle muscular dystrophies (LGMD). Earlier in May 2018, Sarepta and Myonexus inked a partnership to develop Myonexus’ five LGMD gene therapy candidates, which target the most severe and common forms of the disease. As part of the agreement, Sarepta has an exclusive option to acquire Myonexus.
